Director Retirement sets next private placementSets the stage for the next Private Placement....Last weeks announcement old re-cycled news.... Amorfix's CEO letter mid 2012, "We are in discussions with a number of big pharmaceutical corporations and mid-sized companies for the non-exclusive license of our human Alzheimers disease diagnostic test."
In the last few days slipped into the old Corporate update on Amorfix's page dated Q4 2013, old information but noted under EP-AD Diagnostic"Big Pharma Company" Pilot clinical sample to begin January" " Exclusive License and Development as a companion diagnostic for early-stage Alzheimer's disease" ....
The announcement last week comes " Amorfix has granted its Collaborator Access" You will continue to see more insider buying and private placements... tucked away with Interinvest Bermuda a company owned by Hans Black a director with Amorfix, whom is paid by Amorfix consulting fee's...This defines Amorfix's true objectives over the last three years advance the science, keep relevant information from shareholders and the investment community, bulid the share worchest of insiders through insider buying and private placements....A licensing fee would only cut into this stradegy....